Recilisib (ON01210, EX-RAD) is a radiation protective agent that activates the activity of AKT and PI3K in cells. It has been studied as a prophylactic (for use before radiation exposure) and a therapeutic (for use after radiation exposure).

 

Brand: BCM

 

Boiling Point: 607.8±55.0 °C(Predicted)

 

Target: PI3K; Akt

 

Signaling Pathways: Cytoskeletal Signaling; PI3K/Akt/mTOR signaling

 

Solubility: Soluble in DMSO. Insoluble in Water; insoluble in Ethanol.

 

pKa: 4.00±0.10(Predicted)

 

Isomeric SMILES: C1=CC(=CC=C1CS(=O)(=O)/C=C/C2=CC=C(C=C2)C(=O)O)Cl  

 

InChIKey: KBEKQQJUNVQLDZ-MDZDMXLPSA-N  

 

InChI: InChI=1S/C16H13ClO4S/c17-15-7-3-13(4-8-15)11-22(20,21)10-9-12-1-5-14(6-2-12)16(18)19/h1-10H,11H2,(H,18,19)/b10-9+

 

Attribute
[Chem Name]	4-[(E)-2-[(4-chlorophenyl)methylsulfonyl]ethenyl]benzoic acid
[Synonym]	Recilisib； ON01210； EX-RAD
[CAS No.]	334969-03-8
[Formula]	C16H13ClO4S
[Molecular]	336.79
[Form]	Powder
[Storage]	Store at -20°C

Goods Tag